

BLACKHAWK PROVIDES UPDATE ON COVID RAPID TEST KIT OPERATIONS

Vancouver, British Columbia – December 22, 2020 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (US OTC:BLRZF) (the “Company”), is pleased to announce that it continues to sell the SARS-CoV-2 IgG / IgM Rapid Test Kits and the ExProbe SARS-CoV-2 Testing Kits. Blackhawk is still awaiting Health Canada interim order to allow for sales of the kits within Canada, as outlined below, but continues to grow the sale of the kits in jurisdictions outside of Canada.

Since entering definitive distribution agreements (the “Distribution Agreement”) to distribute certain diagnostic products, including the ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit (collectively, the “Test Kits”) used in the detection associated with COVID-19, Blackhawk has sold over 5,000 Test Kits with gross sales revenue of approximately \$75,000USD. Sales of the Test Kits have been focused on the United States market. Blackhawk expects the sales to continue to grow as the Covid-19 virus numbers of infections and required testing reaches critical levels in numerous States in the US. With the success of the Blackhawk sales efforts, the distribution agreement has been mutually extended.

In addition, Blackhawk continues to provide the required information to Health Canada in the hopes that it receives the approval to provide the Test Kits throughout Canada.

The Health Canada Interim Order (“IO”) for its SARS-CoV-2 IgG / IgM Rapid Test Kit application was submitted on November 4th, 2020 and the Company received a “*request for additional information*” letter from Health Canada on November 12th. In order to provide a full & comprehensive response to Health Canada materials requested by Health Canada were completed and submitted on December 13th, 2020.

The Health Canada Interim Order (“IO”) for its ExProbe SARS-CoV-2 Testing Kit was completed and submitted November 13th 2020 and is currently listed as “Under Review”.

Both the ExProbe SARS-CoV-2 and SARS-CoV-2 IgG / IgM Rapid Test Kit are currently USA FDA EUA Authorized and carry a CE mark overseas.

Blackhawk makes no representations or provides any guarantees on Health Canada’s review timelines.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Corporation within the meaning of applicable securities laws, including with respect to completion and review by Health Canada of interim order applications, and increases in sales of test kits. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Corporation’s public filings under the Corporation’s SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.